Data were retrieved from a computerized database. For every woman, the following background information was documented: age, body mass index, tobacco smoking status, obstetric history, infertility type (primary or secondary), duration and aetiology of infertility, basal FSH concentration and antral follicle count. Data were collected on the COVID-19 status of the women: whether they were vaccinated for COVID-19, had recovered from a COVID-19 infection, or were non-infected/unvaccinated. For all participants, a blood test was taken for anti-COVID-19 antibodies and AMH concentration. Serum AMH concentrations were compared with the baseline AMH concentration that had been measured within 12 months prior to recruitment into the study.
Serum AMH concentrations were measured on a Cobas e 801 analyser (Roche Diagnostics, Germany) using an Elecsys AMH Plus Immunoassay (measurement range 0.01–23 ng/ml). The samples for SARS-CoV-2 antibodies were sent for evaluation to an accredited laboratory and were considered positive when signal-to-cutoff values were ≥50.0 (Anti SARS-CoV-2 IgG Quant, Abbott Laboratories, USA). This assay is an automated, two-step immunoassay for the qualitative and quantitative determination of immunoglobulin G antibodies to SARS-CoV-2 in human serum and plasma using chemiluminescent microparticle immunoassay technology.
Serum AMH concentrations were measured on a Cobas e 801 analyser (Roche Diagnostics, Germany) using an Elecsys AMH Plus Immunoassay (measurement range 0.01–23 ng/ml). The samples for SARS-CoV-2 antibodies were sent for evaluation to an accredited laboratory and were considered positive when signal-to-cutoff values were ≥50.0 (Anti SARS-CoV-2 IgG Quant, Abbott Laboratories, USA). This assay is an automated, two-step immunoassay for the qualitative and quantitative determination of immunoglobulin G antibodies to SARS-CoV-2 in human serum and plasma using chemiluminescent microparticle immunoassay technology.